Immunicum has announced that it has signed a collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany for the checkpoint inhibitor (CPI) Bavencio to be used in combination with ilixadencel in the Phase Ib/II ILIAD study. Bavencio (avelumab) is marketed by Pfizer and Merck KGaA, and approved in the US and EU. The availability of Bavencio at no cost to Immunicum in the ILIAD study potentially opens up European study sites, which will be aided by the recent share issues.
19 Nov 2018
Immunicum - Collaboration and supply agreement signed
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Immunicum - Collaboration and supply agreement signed
Immunicum has announced that it has signed a collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany for the checkpoint inhibitor (CPI) Bavencio to be used in combination with ilixadencel in the Phase Ib/II ILIAD study. Bavencio (avelumab) is marketed by Pfizer and Merck KGaA, and approved in the US and EU. The availability of Bavencio at no cost to Immunicum in the ILIAD study potentially opens up European study sites, which will be aided by the recent share issues.